Alvin Shih, M.D. resigned as Executive Vice President of Research and Development of Retrophin Inc (NASDAQ:RTRX), effective as of October 31, 2016. Following the effectiveness of his resignation, Dr. Shih has agreed to serve as a consultant to the Company. The Company has initiated a search for a permanent successor to Dr. Shih. In the interim, Stephen Aselage, the Company’s Chief Executive Officer, will assume responsibility of the Company’s research and development organization.